Trial Profile
A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE TREATMENT OF ANDROGENETIC ALOPECIA IN MALES
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Clascoterone (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Cassiopea
- 16 Apr 2019 Primary endpoint has been met. (2. HGA score at Month 12.), according to a Cassiopea media release.
- 16 Apr 2019 Primary endpoint has been met. (Co-primary efficacy end points include:), according to a Cassiopea media release.
- 16 Apr 2019 Results presented in a Cassiopea media release.